Cargando…
Glycosylation in Indolent, Significant and Aggressive Prostate Cancer by Automated High-Throughput N-Glycan Profiling
The diagnosis and treatment of prostate cancer (PCa) is a major health-care concern worldwide. This cancer can manifest itself in many distinct forms and the transition from clinically indolent PCa to the more invasive aggressive form remains poorly understood. It is now universally accepted that gl...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7730228/ https://www.ncbi.nlm.nih.gov/pubmed/33287410 http://dx.doi.org/10.3390/ijms21239233 |
_version_ | 1783621635154116608 |
---|---|
author | Gilgunn, Sarah Murphy, Keefe Stöckmann, Henning Conroy, Paul J. Murphy, T. Brendan Watson, R. William O’Kennedy, Richard J. Rudd, Pauline M. Saldova, Radka |
author_facet | Gilgunn, Sarah Murphy, Keefe Stöckmann, Henning Conroy, Paul J. Murphy, T. Brendan Watson, R. William O’Kennedy, Richard J. Rudd, Pauline M. Saldova, Radka |
author_sort | Gilgunn, Sarah |
collection | PubMed |
description | The diagnosis and treatment of prostate cancer (PCa) is a major health-care concern worldwide. This cancer can manifest itself in many distinct forms and the transition from clinically indolent PCa to the more invasive aggressive form remains poorly understood. It is now universally accepted that glycan expression patterns change with the cellular modifications that accompany the onset of tumorigenesis. The aim of this study was to investigate if differential glycosylation patterns could distinguish between indolent, significant, and aggressive PCa. Whole serum N-glycan profiling was carried out on 117 prostate cancer patients’ serum using our automated, high-throughput analysis platform for glycan-profiling which utilizes ultra-performance liquid chromatography (UPLC) to obtain high resolution separation of N-linked glycans released from the serum glycoproteins. We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease. These changes give us an insight into the disease pathogenesis and identify potential biomarkers for monitoring the PCa progression, however these need further confirmation studies. |
format | Online Article Text |
id | pubmed-7730228 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-77302282020-12-12 Glycosylation in Indolent, Significant and Aggressive Prostate Cancer by Automated High-Throughput N-Glycan Profiling Gilgunn, Sarah Murphy, Keefe Stöckmann, Henning Conroy, Paul J. Murphy, T. Brendan Watson, R. William O’Kennedy, Richard J. Rudd, Pauline M. Saldova, Radka Int J Mol Sci Article The diagnosis and treatment of prostate cancer (PCa) is a major health-care concern worldwide. This cancer can manifest itself in many distinct forms and the transition from clinically indolent PCa to the more invasive aggressive form remains poorly understood. It is now universally accepted that glycan expression patterns change with the cellular modifications that accompany the onset of tumorigenesis. The aim of this study was to investigate if differential glycosylation patterns could distinguish between indolent, significant, and aggressive PCa. Whole serum N-glycan profiling was carried out on 117 prostate cancer patients’ serum using our automated, high-throughput analysis platform for glycan-profiling which utilizes ultra-performance liquid chromatography (UPLC) to obtain high resolution separation of N-linked glycans released from the serum glycoproteins. We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease. These changes give us an insight into the disease pathogenesis and identify potential biomarkers for monitoring the PCa progression, however these need further confirmation studies. MDPI 2020-12-03 /pmc/articles/PMC7730228/ /pubmed/33287410 http://dx.doi.org/10.3390/ijms21239233 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gilgunn, Sarah Murphy, Keefe Stöckmann, Henning Conroy, Paul J. Murphy, T. Brendan Watson, R. William O’Kennedy, Richard J. Rudd, Pauline M. Saldova, Radka Glycosylation in Indolent, Significant and Aggressive Prostate Cancer by Automated High-Throughput N-Glycan Profiling |
title | Glycosylation in Indolent, Significant and Aggressive Prostate Cancer by Automated High-Throughput N-Glycan Profiling |
title_full | Glycosylation in Indolent, Significant and Aggressive Prostate Cancer by Automated High-Throughput N-Glycan Profiling |
title_fullStr | Glycosylation in Indolent, Significant and Aggressive Prostate Cancer by Automated High-Throughput N-Glycan Profiling |
title_full_unstemmed | Glycosylation in Indolent, Significant and Aggressive Prostate Cancer by Automated High-Throughput N-Glycan Profiling |
title_short | Glycosylation in Indolent, Significant and Aggressive Prostate Cancer by Automated High-Throughput N-Glycan Profiling |
title_sort | glycosylation in indolent, significant and aggressive prostate cancer by automated high-throughput n-glycan profiling |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7730228/ https://www.ncbi.nlm.nih.gov/pubmed/33287410 http://dx.doi.org/10.3390/ijms21239233 |
work_keys_str_mv | AT gilgunnsarah glycosylationinindolentsignificantandaggressiveprostatecancerbyautomatedhighthroughputnglycanprofiling AT murphykeefe glycosylationinindolentsignificantandaggressiveprostatecancerbyautomatedhighthroughputnglycanprofiling AT stockmannhenning glycosylationinindolentsignificantandaggressiveprostatecancerbyautomatedhighthroughputnglycanprofiling AT conroypaulj glycosylationinindolentsignificantandaggressiveprostatecancerbyautomatedhighthroughputnglycanprofiling AT murphytbrendan glycosylationinindolentsignificantandaggressiveprostatecancerbyautomatedhighthroughputnglycanprofiling AT watsonrwilliam glycosylationinindolentsignificantandaggressiveprostatecancerbyautomatedhighthroughputnglycanprofiling AT okennedyrichardj glycosylationinindolentsignificantandaggressiveprostatecancerbyautomatedhighthroughputnglycanprofiling AT ruddpaulinem glycosylationinindolentsignificantandaggressiveprostatecancerbyautomatedhighthroughputnglycanprofiling AT saldovaradka glycosylationinindolentsignificantandaggressiveprostatecancerbyautomatedhighthroughputnglycanprofiling |